Les inhibiteurs sélectifs de la cyclooxygénase de type 2: moins d'effets rénaux que les anti-inflammatoires non stéroïdiens classiques [Selective inhibitors of type 2 cyclooxygenase: less renal effects than the classical non-steroidal anti-inflammatory agents].

Details

Serval ID
serval:BIB_24E1FFB23B91
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Les inhibiteurs sélectifs de la cyclooxygénase de type 2: moins d'effets rénaux que les anti-inflammatoires non stéroïdiens classiques [Selective inhibitors of type 2 cyclooxygenase: less renal effects than the classical non-steroidal anti-inflammatory agents].
Journal
Néphrologie
Author(s)
Chiolero A., Würzner G., Burnier M.
ISSN
0250-4960 (Print)
ISSN-L
0250-4960
Publication state
Published
Issued date
2000
Volume
21
Number
8
Pages
425-430
Language
french
Notes
Publication types: Comparative Study ; English Abstract ; Journal Article ; Review
Publication Status: ppublish
Abstract
Prostaglandins play an important role in the regulation of renal hemodynamics and sodium excretion. Thus, the administration of non-steroidal anti-inflammatory drugs (NSAIDs) induces a renal vasoconstriction and sodium and potassium retention. In some high risk patients, this may lead to acute renal failure. The anti-inflammatory and renal effects of conventional NSAIDs are mediated by the non-selective inhibition of two cyclo-oxygenases, COX-1 and COX-2. Recently, highly selective COX-2 inhibitors have been developed such as celecoxib (Celebrex) and rofecoxib (Vioxx). These drugs were designed to preserve the analgesic and anti-inflammatory properties of NSAIDs while reducing their gastro-intestinal and renal side effects. Selective COX-2 inhibitors have indeed less gastro-intestinal side-effects. However, their renal profile is comparable to that of non-selective inhibitors as they induce a decrease in glomerular filtration rate and a sodium and potassium retention. Thus, despite the good gastro-intestinal safety profile of selective COX-2, one should be careful with the use of these agents in high risk patients as they may induce similar renal complications as non-selective NSAIDs.
Keywords
Anti-Inflammatory Agents, Non-Steroidal/adverse effects, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors, Cyclooxygenase Inhibitors/adverse effects, Cyclooxygenase Inhibitors/therapeutic use, Gastrointestinal Diseases/chemically induced, Humans, Isoenzymes/analysis, Isoenzymes/antagonists & inhibitors, Kidney/drug effects, Kidney/enzymology, Kidney Diseases/chemically induced, Kidney Diseases/prevention & control, Membrane Proteins, Prostaglandin-Endoperoxide Synthases/analysis, Prostaglandins/physiology, Renin/secretion
Pubmed
Web of science
Create date
25/01/2008 12:56
Last modification date
20/08/2019 13:03
Usage data